We enjoyed our first joint webinar with PharmaMedic and Triducive of 2022. Our guest speakers, Dr Malcolm Barratt-Johnson (PharmaMedic) and Tim Warren (Triducive) joined Nick Williams (Triducive) for a discussion and interactive Q&A on the evolving and increasingly strategic role of medical affairs within pharma and life sciences businesses. Read on for the key takeaways.
In the UK, we now seem to be moving into a new phase of pandemic management, with the government aiming to” transition to managing COVID-19 like other respiratory illnesses”. In their recent March 2022 statement, the government attributes this evolution in approach to vaccines and treatments. In this short article, we overview the current role of antivirals and monoclonal antibodies and look ahead to future developments in our attempt to manage the day-to day risks of living with COVID-19.
Join Triducive and PharmaMedic for an interactive webinar on Thursday 28th April at 8.00AM. Keynote speakers Dr Malcolm Barratt-Johnson and Tim Warren will be discussing the strategic role of medical affairs in Pharma and the potential role of Delphi based studies for strategic impact. Find out more.
Non-Executive Directors play an integral role for any organisation, not least within the life science space where leadership often needs to draw on a broad range of strategic and tactical expertise to drive the business forward. In this short Q&A article, we interview PharmaMedic Managing Director Dr Malcolm Barratt-Johnson about the value that a pharmaceutical physician delivers in the role of NED.
PharmaMedic is delighted to announce our next virtual breakfast briefing on Thursday 24th February 2022 at 8 am. For this virtual session, we invite you to join experts Dr Malcolm Barratt-Johnson, Mr Guy Francis, Dr Lucy Cook and Mr Andrew Wise for a lively panel discussion tackling the key industry and medical affairs trends we expect to emerge in 2022 and how we can best adapt to succeed. Learn more about the agenda and register here.
Against a backdrop of achievements yielded from public/private collaborations in the context of the pandemic response, we focused our latest virtual briefing on the crucial role such partnerships play in furthering biopharma and medical devices innovation. We share highlights from the event and provide the catch-up recording in this brief summary.
PMC was delighted to feature in the latest LBIC newsletter from the London BioScience Innovation Centre discussing how the ILAP scheme is helping to secure the UK’s position as a life science superpower. Learn more.
In March 2021, the government published its document Saving and Improving lives: The Future of Clinical Research Delivery. The paper laid out an ambitious vision for a more patient-centred, pro-innovation and data-enabled clinical research environment in the UK. Following the publication of the implementation plan in June, we summarise the key themes in this article.
Join PMC for our next virtual breakfast briefing on Wednesday 21st July 2021 at 8am. Our topic for this session is “The role of public/ private collaborations to further biopharma and medical devices innovation”. We are delighted to welcome Nicki Bromwich, Chief Operating Officer of MedCity who will join Dr Malcolm Barratt-Johnson, Managing Director of PMC to discuss the ecosystem of public/ private collaboration and how it supports innovation. Read more and register.
The MHRA's recently launched Innovative Licensing and Access Pathway scheme (ILAP) forms part of a bold vision for the UK to incentivise and support life sciences development as we emerge into a post-Brexit regulatory and clinical trials environment. PharmaMedic Consultancy is currently supporting several clients with their applications, and in this article, we share more insights about the scheme and how it stands to benefit patients and sponsors.
